Cardioxane--ICRF-187 towards anticancer drug specificity through selective toxicity reduction
Cancer Treat Rev
.
1991 Mar;18(1):1-19.
doi: 10.1016/0305-7372(91)90002-h.
Authors
J Koning
1
,
P Palmer
,
C R Franks
,
D E Mulder
,
J L Speyer
,
M D Green
,
K Hellmann
Affiliation
1
EuroCetus B.V., Amsterdam, The Netherlands.
PMID:
1933909
DOI:
10.1016/0305-7372(91)90002-h
No abstract available
Publication types
Review
MeSH terms
Animals
Antineoplastic Agents / adverse effects*
Heart / drug effects*
Humans
Razoxane / pharmacology*
Substances
Antineoplastic Agents
Razoxane